218 related articles for article (PubMed ID: 35806472)
1. Limited Accuracy of Pan-Trk Immunohistochemistry Screening for
Macerola E; Proietti A; Poma AM; Vignali P; Sparavelli R; Ginori A; Basolo A; Elisei R; Santini F; Basolo F
Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806472
[TBL] [Abstract][Full Text] [Related]
2. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
[TBL] [Abstract][Full Text] [Related]
3. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
[TBL] [Abstract][Full Text] [Related]
4. A systematic comparison of pan-Trk immunohistochemistry assays among multiple cancer types.
Haberecker M; Töpfer A; Melega F; Moch H; Pauli C
Histopathology; 2023 Jun; 82(7):1003-1012. PubMed ID: 36759438
[TBL] [Abstract][Full Text] [Related]
5. Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions.
Brčić I; Godschachner TM; Bergovec M; Igrec J; Till H; Lackner H; Scheipl S; Kashofer K; Brodowicz T; Leithner A; Szkandera J; Liegl-Atzwanger B
Mod Pathol; 2021 Feb; 34(2):396-407. PubMed ID: 32860002
[TBL] [Abstract][Full Text] [Related]
6. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing.
Koehne de González A; Mansukhani MM; Fernandes H; Hsiao SJ
Cancer Genet; 2022 Apr; 262-263():47-52. PubMed ID: 35007853
[TBL] [Abstract][Full Text] [Related]
7. Detection of NTRK1/3 Rearrangements in Papillary Thyroid Carcinoma Using Immunohistochemistry, Fluorescent In Situ Hybridization, and Next-Generation Sequencing.
Lee YC; Chen JY; Huang CJ; Chen HS; Yang AH; Hang JF
Endocr Pathol; 2020 Dec; 31(4):348-358. PubMed ID: 32880785
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
[TBL] [Abstract][Full Text] [Related]
9. Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors.
Rudzinski ER; Lockwood CM; Stohr BA; Vargas SO; Sheridan R; Black JO; Rajaram V; Laetsch TW; Davis JL
Am J Surg Pathol; 2018 Jul; 42(7):927-935. PubMed ID: 29683818
[TBL] [Abstract][Full Text] [Related]
10. Pan-TRK Immunohistochemistry Is Highly Correlated With NTRK3 Gene Rearrangements in Salivary Gland Tumors.
Csanyi-Bastien M; Lanic MD; Beaussire L; Ferric S; François A; Meseure D; Jardin F; Wassef M; Ruminy P; Laé M
Am J Surg Pathol; 2021 Nov; 45(11):1487-1498. PubMed ID: 33899788
[TBL] [Abstract][Full Text] [Related]
11. Screening for NTRK-rearranged Tumors Using Immunohistochemistry: Comparison of 2 Different pan-TRK Clones in Melanoma Samples.
Bourhis A; Redoulez G; Quintin-Roué I; Marcorelles P; Uguen A
Appl Immunohistochem Mol Morphol; 2020 Mar; 28(3):194-196. PubMed ID: 30920961
[TBL] [Abstract][Full Text] [Related]
12. Using pan-TRK and RET Immunohistochemistry for the Detection of Fusion Types of Salivary Gland Secretory Carcinoma.
Su YJ; Lee YH; Jin YT; Hsieh MS
Appl Immunohistochem Mol Morphol; 2022 Apr; 30(4):264-272. PubMed ID: 35384876
[TBL] [Abstract][Full Text] [Related]
13. EPR17341 and A7H6R pan-TRK Immunohistochemistry Result in Highly Different Staining Patterns in a Series of Salivary Gland Tumors.
Guibourg B; Cloarec E; Conan-Charlet V; Quintin-Roué I; Grippari JL; Le Flahec G; Marcorelles P; Uguen A
Appl Immunohistochem Mol Morphol; 2020 Oct; 28(9):719-724. PubMed ID: 32187023
[TBL] [Abstract][Full Text] [Related]
14. The sensitivity of pan-TRK immunohistochemistry in solid tumours: A meta-analysis.
Hondelink LM; Schrader AMR; Asri Aghmuni G; Solleveld-Westerink N; Cleton-Jansen AM; van Egmond D; Boot A; Ouahoud S; Khalifa MN; Wai Lam S; Morreau H; Bovee JVMG; van Wezel T; Cohen D
Eur J Cancer; 2022 Sep; 173():229-237. PubMed ID: 35933886
[TBL] [Abstract][Full Text] [Related]
15. The Pan-TRK Antibody is a Sensitive and Specific Tool for the Detection of NTRK Fusion Genes.
Bautista-Wong C; Mojica-González Z; Hop-Garcia K; Bornstein Quevedo L
Appl Immunohistochem Mol Morphol; 2023 Apr; 31(4):213-216. PubMed ID: 37017998
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of the methods for detecting NTRK gene fusion variations in papillary thyroid carcinoma].
Jiang YY; Chen H; Xu BL; Wang S
Zhonghua Bing Li Xue Za Zhi; 2022 Aug; 51(8):726-732. PubMed ID: 35922162
[No Abstract] [Full Text] [Related]
17. NTRK Fusion in a Cohort of BRAF p. V600E Wild-Type Papillary Thyroid Carcinomas.
Lee SE; Lee MS; Bang H; Kim MY; Choi YL; Oh YL
Mod Pathol; 2023 Aug; 36(8):100180. PubMed ID: 37003481
[TBL] [Abstract][Full Text] [Related]
18. The Diagnostic Value of Pan-Trk Expression to Detect Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion in CNS Tumours: A Study Using Next-Generation Sequencing Platform.
Mohamed F; Kurdi M; Baeesa S; Sabbagh AJ; Hakamy S; Maghrabi Y; Alshedokhi M; Dallol A; Halawa TF; Najjar AA; Fdl-Elmula I
Pathol Oncol Res; 2022; 28():1610233. PubMed ID: 35295612
[No Abstract] [Full Text] [Related]
19. Pan-TRK immunohistochemistry in gynaecological mesenchymal tumours: diagnostic implications and pitfalls.
Moura MS; Costa J; Velasco V; Kommoss F; Oliva E; Le Loarer F; McCluggage WG; Razack R; Treilleux I; Mills A; Longacre T; Devouassoux-Shisheboran M; Hostein I; Azmani R; Blanchard L; Hartog C; Soubeyran I; Khalifa E; Croce S
Histopathology; 2024 Feb; 84(3):451-462. PubMed ID: 37988282
[TBL] [Abstract][Full Text] [Related]
20. Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma.
Yamamoto H; Nozaki Y; Sugii A; Taguchi K; Hongo T; Jiromaru R; Sato M; Nakano T; Hashimoto K; Fujiwara M; Oda Y
Hum Pathol; 2021 Mar; 109():37-44. PubMed ID: 33301751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
